Thus the potential to exploit this adaptation for therapeutic effect seems particularly attractive and we argue that the studies presented here provide evidence of the direct functional link between p53 status and tumour metabolism in SCCHN cells that could be readily exploited by combining a glycolytic inhibitor with standard radiotherapy for patient benefit. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.